Long‐term mortality with cardiac resynchronization therapy in the Cardiac Resynchronization‐Heart Failure (CARE‐HF) trial

Author:

Cleland John G.F.1,Freemantle Nick2,Erdmann Erland3,Gras Daniel4,Kappenberger Lukas5,Tavazzi Luigi6,Daubert Jean‐Claude7

Affiliation:

1. Department of Cardiology Castle Hill Hospital, University of Hull Kingston upon Hull UK

2. University of Birmingham Edgbaston UK

3. Klinik III für Innere Medizin der Universität zu Köln Cologne Germany

4. Nouvelles Cliniques Nantaises Nantes France

5. University of Lausanne Switzerland

6. GVM Care and Research, Maria Cecilia Hospital Cotignola Italy

7. Département de Cardiologie Hôpital Pontchaillou Rennes France

Abstract

AimsThe Cardiac Resynchronization‐Heart Failure (CARE‐HF) study helped establish an important role for cardiac resynchronization therapy (CRT) in the management of selected patients with heart failure. We now report the long‐term outcome during and subsequent to the randomized trial.Methods and resultsEnrolment was completed in March 2003. After reporting the main study results in 2005, investigators were asked to inform patients of the results and implant a CRT device if still appropriate. Subsequently, investigators were asked to consent patients for long‐term follow‐up until 30 September 2009. Of 813 patients originally enrolled, 343 (42%) died prior to re‐consent, 111 patients (14%) were not or could not be contacted, 50 (6%) were alive but declined to participate, and 309 (38%) consented to long‐term follow‐up. Of patients originally assigned to the control group, > 95% of survivors had received CRT by the time of re‐consent. From the time of randomization, 222 patients originally assigned to pharmacological therapy and 192 originally assigned to CRT were known to have died. The hazard ratio for mortality in patients originally assigned to CRT compared with those originally assigned to the control group was 0.77 (95% confidence interval 0.63–0.93; P = 0.007). No subgroup interactions were observed.ConclusionThe effect of CRT on mortality observed during the randomized CARE‐HF trial persisted during long‐term follow‐up. A high rate of CRT device implantation in the control group after completion of the randomized phase of the study may have prevented further divergence of the survival curves.

Publisher

Wiley

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.7亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2025 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3